JAK1 and renal cell carcinoma: After CHX treatment, JAK1 was rapidly degraded in RCC cells with EHBP1L1 knockdown (Figure 6C; Figure S6B, Supporting Information), whereas JAK1 protein had a significantly increased half‐life in cells with EHBP1L1 overexpression (Figure 6D; Figure S6C, Supporting Information).